This brand name is authorized in South Africa
The drug MIGLAN contains one active pharmaceutical ingredient (API):
|
1
Rizatriptan
UNII WR978S7QHH - RIZATRIPTAN BENZOATE
|
|
Rizatriptan binds selectively with high affinity to human 5-HT1B and 5-HT1D receptors. The therapeutic activity of rizatriptan in treating migraine headache may be attributed to its agonist effects at 5-HT1B and 5-HT1D receptors on the extracerebral intracranial blood vessels that are thought to become dilated during an attack and on the trigeminal sensory nerves that innervate them. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N02CC04 | Rizatriptan | N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CC Selective serotonin (5HT1) agonists |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: ZA | Health Products Regulatory Authority | Identifier(s): 49/7.3/0553, 49/7.3/0554 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
